165 related articles for article (PubMed ID: 33180025)
1. Advanced Symptom Management System for Patients with Malignant Pleural Mesothelioma (ASyMSmeso): Mixed Methods Study.
Maguire R; Connaghan J; Arber A; Klepacz N; Blyth KG; McPhelim J; Murray P; Rupani H; Chauhan A; Williams P; McNaughton L; Woods K; Moylan A
J Med Internet Res; 2020 Nov; 22(11):e19180. PubMed ID: 33180025
[TBL] [Abstract][Full Text] [Related]
2. A Pilot Mixed-Methods Study of Malignant Pleural Mesothelioma Symptoms.
Walker SL; Vaughan Dickson V; Cacchione PZ
Oncol Nurs Forum; 2022 Oct; 49(6):615-623. PubMed ID: 36413739
[TBL] [Abstract][Full Text] [Related]
3. Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
Williams LA; Whisenant MS; Mendoza TR; Haq S; Keating KN; Cuffel B; Cleeland CS
Qual Life Res; 2018 Dec; 27(12):3229-3241. PubMed ID: 30187393
[TBL] [Abstract][Full Text] [Related]
4. Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.
Moore A; Bennett B; Taylor-Stokes G; McDonald L; Daumont MJ
BMC Cancer; 2022 Jun; 22(1):693. PubMed ID: 35739480
[TBL] [Abstract][Full Text] [Related]
5. Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso.
Hollen PJ; Gralla RJ; Liepa AM; Symanowski JT; Rusthoven JJ
Support Care Cancer; 2006 Jan; 14(1):11-21. PubMed ID: 15999264
[TBL] [Abstract][Full Text] [Related]
6. Content validity and electronic PRO (ePRO) usability of the Lung Cancer Symptom Scale-Mesothelioma (LCSS-Meso) in mesothelioma patients.
Gelhorn HL; Skalicky AM; Balantac Z; Eremenco S; Cimms T; Halling K; Hollen PJ; Gralla RJ; Mahoney MC; Sexton C
Support Care Cancer; 2018 Jul; 26(7):2229-2238. PubMed ID: 29392480
[TBL] [Abstract][Full Text] [Related]
7. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.
Hollen PJ; Gralla RJ; Liepa AM; Symanowski JT; Rusthoven JJ
Cancer; 2004 Aug; 101(3):587-95. PubMed ID: 15274072
[TBL] [Abstract][Full Text] [Related]
8. The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey.
Ben Bouazza Y; Van Meerbeeck JP
Transl Lung Cancer Res; 2018 Oct; 7(5):507-515. PubMed ID: 30450288
[TBL] [Abstract][Full Text] [Related]
9. Symptom Burden and Unmet Needs in Malignant Pleural Mesothelioma: Exploratory Analyses From the RESPECT-Meso Study.
Hoon SN; Lawrie I; Qi C; Rahman N; Maskell N; Forbes K; Gerry S; Monterosso L; Chauhan A; Brims FJH
J Palliat Care; 2021 Apr; 36(2):113-120. PubMed ID: 32791881
[TBL] [Abstract][Full Text] [Related]
10. Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion.
Zhang S; Zhang Y; Feng W; Shi Z; Shi H; Zhang Y
Thorac Cancer; 2021 Dec; 12(24):3304-3309. PubMed ID: 34704370
[TBL] [Abstract][Full Text] [Related]
11. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
[TBL] [Abstract][Full Text] [Related]
12. Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma.
Warby A; Dhillon HM; Kao S; Vardy JL
Support Care Cancer; 2019 Sep; 27(9):3509-3519. PubMed ID: 30684047
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study.
Trama A; Proto C; Signorelli D; Garassino MC; Lo Russo G; Ganzinelli M; Prelaj A; Mensi C; Gangemi M; Gennaro V; Chellini E; Caldarella A; Angelillo IF; Ascoli V; Pascucci C; Tagliabue G; Cusimano R; Bella F; Falcini F; Merler E; Masanotti G; Ziino A; Michiara M; Gola G; Storchi C; Mangone L; Vitale MF; Cirilli C; Tumino R; Scuderi T; Fanetti AC; Piffer S; Tiseo M; Gatta G; Botta L;
Thorac Cancer; 2020 Jun; 11(6):1661-1669. PubMed ID: 32364316
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel remote patient monitoring system: the advanced symptom management system for radiotherapy to improve the symptom experience of patients with lung cancer receiving radiotherapy.
Maguire R; Ream E; Richardson A; Connaghan J; Johnston B; Kotronoulas G; Pedersen V; McPhelim J; Pattison N; Smith A; Webster L; Taylor A; Kearney N
Cancer Nurs; 2015; 38(2):E37-47. PubMed ID: 24836956
[TBL] [Abstract][Full Text] [Related]
15. Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.
Nagamatsu Y; Oze I; Aoe K; Hotta K; Kato K; Nakagawa J; Hara K; Kishimoto T; Fujimoto N
BMC Cancer; 2018 Mar; 18(1):350. PubMed ID: 29587685
[TBL] [Abstract][Full Text] [Related]
16. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.
Gutierrez-Sainz L; Cruz P; Martinez-Recio S; Higuera O; Esteban-Rodriguez MI; Arias-Lotto F; Gonzalez RA; De Castro-Carpeño J
Clin Transl Oncol; 2021 Oct; 23(10):2030-2035. PubMed ID: 33837910
[TBL] [Abstract][Full Text] [Related]
17. Usability Evaluation of a Mobile Phone-Based System for Remote Monitoring and Management of Chemotherapy-Related Side Effects in Cancer Patients: Mixed-Methods Study.
Moradian S; Krzyzanowska MK; Maguire R; Morita PP; Kukreti V; Avery J; Liu G; Cafazzo J; Howell D
JMIR Cancer; 2018 Dec; 4(2):e10932. PubMed ID: 30578238
[TBL] [Abstract][Full Text] [Related]
18. A survey of patient and caregiver experience with malignant pleural mesothelioma.
Warby A; Dhillon HM; Kao S; Vardy JL
Support Care Cancer; 2019 Dec; 27(12):4675-4686. PubMed ID: 30944991
[TBL] [Abstract][Full Text] [Related]
19. A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial.
Gunatilake S; Brims FJ; Fogg C; Lawrie I; Maskell N; Forbes K; Rahman N; Morris S; Ogollah R; Gerry S; Peake M; Darlison L; Chauhan AJ
Trials; 2014 Sep; 15():367. PubMed ID: 25238873
[TBL] [Abstract][Full Text] [Related]
20. Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma.
Barsky AR; Ahern CA; Venigalla S; Verma V; Anstadt EJ; Wright CM; Ludmir EB; Berlind CG; Lindsay WD; Grover S; Cengel KA; Simone CB
Clin Lung Cancer; 2020 Nov; 21(6):e583-e591. PubMed ID: 32611504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
